RLMD Latest Press Releases

-- January 12, 2026 --

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications Globe Newswire 7:00 AM

-- December 3, 2025 --

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology Globe Newswire 7:30 AM

-- November 13, 2025 --

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates Globe Newswire 4:01 PM

-- November 7, 2025 --

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 Globe Newswire 7:30 AM

-- November 4, 2025 --

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Globe Newswire 7:09 AM

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer Globe Newswire 7:01 AM

-- October 7, 2025 --

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 Globe Newswire 7:30 AM

-- September 16, 2025 --

Sidoti Events, LLC's Virtual September Small-Cap Conference ACCESS Newswire 11:20 AM

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement Globe Newswire 9:00 AM

-- September 10, 2025 --

Relmada Issues Mid-Year CEO Letter to Shareholders Globe Newswire 7:15 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software